Giannis Dimitrios, Moris Dimitrios, Barbas Andrew S
Institute of Health Innovations and Outcomes Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY 11030, USA.
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Cancers (Basel). 2021 Mar 3;13(5):1071. doi: 10.3390/cancers13051071.
Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic malignancy and is associated with aggressive tumor behavior and poor prognosis. Most patients with PDAC present with an advanced disease stage and treatment-resistant tumors. The lack of noninvasive tests for PDAC diagnosis and survival prediction mandates the identification of novel biomarkers. The early identification of high-risk patients and patients with PDAC is of utmost importance. In addition, the identification of molecules that are associated with tumor biology, aggressiveness, and metastatic potential is crucial to predict survival and to provide patients with personalized treatment regimens. In this review, we summarize the current literature and focus on newer biomarkers, which are continuously added to the armamentarium of PDAC screening, predictive tools, and prognostic tools.
胰腺导管腺癌（PDAC）是最常见的胰腺恶性肿瘤，与侵袭性肿瘤行为和不良预后相关。大多数PDAC患者就诊时已处于疾病晚期且肿瘤具有治疗抵抗性。缺乏用于PDAC诊断和生存预测的非侵入性检测方法，这就需要识别新的生物标志物。早期识别高危患者和PDAC患者至关重要。此外，识别与肿瘤生物学、侵袭性和转移潜能相关的分子对于预测生存以及为患者提供个性化治疗方案至关重要。在本综述中，我们总结了当前的文献，并聚焦于更新的生物标志物，这些生物标志物不断被纳入到PDAC筛查、预测工具和预后工具中。
